Immediate Impact
6 by Nobel laureates 30 from Science/Nature 58 standout
Citing Papers
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
2025 Standout
Pharmacology and Clinical Development of Factor XI Inhibitors
2023 Standout
Works of Stephan Schwers being referenced
First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men
2022
BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Stephan Schwers | 260 | 372 | 195 | 479 | 25 | 1.2k | |
| Goichi Honda | 716 | 255 | 105 | 252 | 38 | 1.5k | |
| Maria Cecília S. Freitas | 204 | 465 | 158 | 365 | 21 | 1.5k | |
| Vincenzo Toschi | 658 | 560 | 120 | 269 | 46 | 1.5k | |
| Michael Tencati | 515 | 196 | 123 | 470 | 17 | 1.4k | |
| Susanne Pfeiler | 321 | 149 | 82 | 793 | 24 | 1.6k | |
| PW Majerus | 846 | 251 | 137 | 112 | 20 | 1.3k | |
| L A Harker | 306 | 156 | 57 | 453 | 24 | 1.6k | |
| Ichiro Kumabashiri | 407 | 189 | 80 | 256 | 43 | 1.3k | |
| Takayuki Iwaki | 312 | 155 | 220 | 182 | 41 | 1.0k | |
| Suzanne Fateh‐Moghadam | 377 | 610 | 49 | 251 | 36 | 1.5k |
All Works
Login with ORCID to disown or claim papers
Loading papers...